Capstone Investment Advisors
ALT icon

Capstone Investment Advisors’s Altimmune ALT Stock Holding History

Capstone Investment Advisors’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-75,000
Closed -$317K – 1828
2023
Q1 		$317K Buy
+75,000
New +$891K ﹤0.01% 1156

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Capstone Investment Advisors's ALT Position: Q2 2023 in Review

Capstone Investment Advisors sold out of Altimmune (ALT) in Q2 2023, closing a stake of 86 shares — an estimated $363 sold.

Capstone Investment Advisors first reported a position in ALT in Q4 2020 and held it in 2 quarters. The position peaked at $267K in Q4 2020. 120 funds tracked by Wall St. Rank hold ALT as of Q2 2023.

  • Capstone Investment Advisors reported no remaining Altimmune position as of Q2 2023 after selling out during the quarter.
  • Capstone Investment Advisors sold 86 Altimmune shares in Q2 2023, an estimated $363.
  • Capstone Investment Advisors first reported a position in Altimmune in Q4 2020 and held it in 2 quarters.
  • Capstone Investment Advisors's Altimmune position peaked at $267K in Q4 2020.
  • 120 funds tracked by Wall St. Rank held Altimmune as of Q2 2023.

Based on Capstone Investment Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.